Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Crossref DOI link: https://doi.org/10.1007/s40262-017-0528-2
Published Online: 2017-03-27
Published Print: 2017-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Marbury, Thomas C.
Flint, Anne
Jacobsen, Jacob B.
Derving Karsbøl, Julie
Lasseter, Kenneth
Funding for this research was provided by:
Novo Nordisk
License valid from 2017-03-27